Torrent Pharmaceuticals has successfully completed the allotment of four series of non-convertible debentures (NCDs) worth ₹1,099.61 crores on January 19, 2026. The Securities Transfer and Stakeholders Relationship Committee approved this significant debt issuance under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

NCD Allotment Details

The company allotted a total of 11,99,000 senior, secured, redeemable, listed, rated NCDs with a nominal value of ₹1,00,000 each across four distinct series. The allotment details are structured as follows:

Interest Rates and Tenure Structure

The four series offer varying interest rates and tenure periods to cater to different investor preferences. The interest rates increase progressively with longer tenure periods:

Payment Schedule and Security Features

All four series follow an annual payment schedule for both coupon interest and principal redemption. The debentures are secured by a first ranking exclusive charge over:

• The designated account where NCD proceeds will be deposited
• Specified trademarks of the company providing minimum security cover of 1.1x

The NCDs will be redeemed at par value on their respective maturity dates. Series 1 debentures will have two coupon payments before principal redemption, while Series 4 will have five annual coupon payments throughout its tenure.

Listing and Regulatory Compliance

All four series of NCDs will be listed on the Wholesale Debt Market Segment of the National Stock Exchange of India Limited. The issuance was conducted through private placement, and the company has fulfilled all regulatory requirements under SEBI guidelines.

The debenture trust deed executed between the company and the debenture trustee governs the special rights, interests, and privileges attached to these instruments. The company reported no delays in payment obligations or defaults across any of the series.

Source:

Torrent Pharmaceuticals Limited has issued commercial papers worth ₹1,500 crores on January 19, 2026, as per its regulatory filing under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Commercial Paper Details

The pharmaceutical company issued 30,000 listed, rated, transferable, rupee-denominated commercial papers with a face value of ₹5,00,000 each. The instruments are proposed to be listed on the National Stock Exchange of India (NSE).

Financial Terms and Structure

The commercial papers carry a discount rate of 7.20% with an upfront payment schedule for interest. The instruments have a tenure of 337 days and are unsecured in nature.

Regulatory Compliance

The issuance was communicated to both BSE Limited and National Stock Exchange of India Limited as part of the company's regulatory obligations. The filing confirms that there are no special rights, privileges, or charges attached to these instruments, and no delays or defaults are applicable at the time of issuance.

This commercial paper issuance represents a significant short-term financing initiative by Torrent Pharmaceuticals, providing the company with working capital for its operational requirements over the next 11 months.